SN

Saksham Naresh Bajirao

Active Director Director DIN 10883387
DIN 10883387 First appointment Dec 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Saksham Naresh Bajirao

Data last updated:

Saksham Naresh Bajirao is a Director at Miga Pharma Private Limited (since 2024). The company operates in Pharma.

DIN 10883387
Primary Designation Director
Industry Pharma
First Appointment 23 Dec 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Miga Pharma Private Limited U46497DL2024PTC440235
Director23 Dec 20242024Active

Board colleagues of Saksham Naresh Bajirao

NameDINCompanyDesignation
Rajat10883388Miga Pharma Private LimitedDirector
Ram Dayaram Raikohad11316982Miga Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Miga Pharma Private Limited
Premium access

Shareholding and investment profile for Saksham Naresh Bajirao

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Saksham Naresh Bajirao

Saksham Naresh Bajirao currently holds 1 directorship: Miga Pharma Private Limited (Director, since 23 Dec 2024).

Saksham Naresh Bajirao was first appointed on 23 Dec 2024 as Director at Miga Pharma Private Limited.

The current boards of Saksham Naresh Bajirao's companies include Rajat (Miga Pharma Private Limited), Ram Dayaram Raikohad (Miga Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available